So Yeon Cho, Eun Woo Kim, Soo Jin Park, Benjamin U Phillips, Jihyeon Jeong, Hyunjeong Kim, Christopher J Heath, Daehwan Kim, Yurim Jang, Laura López-Cruz, Lisa M Saksida, Timothy J Bussey, Do Yup Lee, Eosu Kim
Metformin, a primary anti-diabetic medication, has been anticipated to provide benefits for Alzheimer's disease (AD), also known as "type 3 diabetes". Nevertheless, some studies have demonstrated that metformin may trigger AD pathology and even elevate AD risk in humans. Despite this, limited research has elucidated the behavioral outcomes of metformin treatment, which would hold significant translational value. Thus, we aimed to perform thorough behavioral research on the prolonged administration of metformin to mice: We administered metformin (300 mg/kg/day) to transgenic 3xTg-AD and non-transgenic (NT) C57BL/6 mice over 1 and 2 years, respectively, and evaluated their behaviors across multiple domains via touchscreen operant chambers, including motivation, attention, memory, visual discrimination, and cognitive flexibility...
January 18, 2024: Translational Psychiatry